National Institute of Neurological Disorders and Stroke (NINDS)

FLC Region

Security Lab



Building 31, Room 8A31
31 Center Drive (MSC 2540)
Bethesda, MD 20824
United States

Want more information? Contact a representative below.

Laboratory Representative


The National Institute of Neurological Disorders and Stroke (NINDS) conducts and supports research on brain and nervous system disorders. Created by the U.S. Congress in 1950, NINDS is one of the more than two dozen research institutes and centers that comprise the National Institutes of Health (NIH). The NIH, located in Bethesda, Maryland, is an agency of the Public Health Service within the U.S. Department of Health and Human Services. NINDS has occupied a central position in the world of neuroscience for 50 years. More than 600 disorders afflict the nervous system. Common disorders such as stroke, epilepsy, Parkinson's disease, and autism are well- known. Many other neurological disorders are rare-known only to the patients and families affected, their doctors, and scientists who look to rare disorders for clues to a general understanding of the brain as well as for treatments for specific diseases. Neurological disorders strike an estimated 50 million Americans each year, exacting an incalculable personal toll and an annual economic cost of hundreds of billions of dollars in medical expenses and lost productivity.


The mission of NINDS is to reduce the burden of neurological disease - a burden borne by every age group, by every segment of society, by people all over the world. To support this mission, NINDS: Conducts, fosters, coordinates, and guides research on the causes, prevention, diagnosis, and treatment of neurological disorders and stroke, and supports basic research in related scientific areas; Provides grants-in-aid to public and private institutions and individuals in fields related to its areas of interest, including research project, program project, and research center grants; Operates a program of contracts for the funding of research and research support efforts in selected areas of institute need; Provides individual and institutional fellowships to increase scientific expertise in neurological fields; Conducts a diversified program of intramural and collaborative research in its own laboratories, branches, and clinics; Collects and disseminates research information related to neurological disorders.

Technology Disciplines

Displaying 1 - 10 of 10
A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency
A Neuronal Avalanche Size (NAS) Assay to Screen for Cognitive Enhancers and Anti-Epileptics
Immunotoxin with in-vivo T cell Suppressant Activity
Ketamine Metabolites for the Treatment of Depression and Pain
Methods for Expression and Purification of Immunotoxins
Methods of Inducing Immune Tolerance Using Immunotoxins
Novel Isoform of KCNH2 for the Treatment of Schizophrenia
Radiotracers for Imaging P-glycoprotein Transporter Function
Serotonin-Deficient Knock-out Mouse
Tyrosyl-DNA Phosphodiesterases (TDP) and Related Polypeptides, Nucleic Acids, Vectors, TDP-Producing Host Cell, Antibodies and Methods of Use
Displaying 1 - 3 of 3
Counter Act Core Resources
NIH NeuroBioBank
The UC Davis/NIH NeuroMab Facility

No Equipment


The CounterACT program is a translational research program supporting basic, translational, and clinical research aimed at the discovery and/or identification of better therapeutic medical countermeasures and/or diagnostic technologies against chemical threat agents, and facilitates their movement through the regulatory process in collaboration with other federal departments and agencies, such as the Biomedical Advanced Research and Development Authority ( HHS BARDA). The program includes a comprehensive network of Research Centers of Excellence, individual co-operative research projects, small business innovation research grants, contracts, and interagency agreements with the Department of Defense.

Funding for Therapeutics Development Projects
  • NINDS Cooperative Program in Translational Research (U01). The milestone-driven program supports preclinical optimization and testing of the leads, and projects must be sufficiently advanced that an Investigational New Drug (IND), Investigational Device Exemption (IDE), 510(k), or 510(k) de novo application to the Food and Drug Administration (FDA) can be submitted during the project period.
  • NINDS Exploratory/Developmental Projects in Translational Research (R21). Funding to support any research activities required to advance development of candidate therapeutics (drugs, devices, and biologics). Projects can be supported prior to or in parallel with cooperative agreement funding.

Guidance and Resources for Therapeutics Development Projects

No Funds


No Publications


No News


No Successes


No Licenses